Home > Full Text Reviews > A Systematic Review and Economic... > Calculation of Crohn's Disease Activity...

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Dretzke J, Edlin R, Round J, et al. A Systematic Review and Economic Evaluation of the Use of Tumour Necrosis Factor-Alpha (TNF-α) Inhibitors, Adalimumab and Infliximab, for Crohn's Disease. Southampton (UK): NIHR Journals Library; 2011 Feb. (Health Technology Assessment, No. 15.6.)

Appendix 1Calculation of Crohn's Disease Activity Index (adapted from Best et al.39)

VariableDescriptionScoringMultiplier
Number of liquid stoolsSum of 7 days×2
Abdominal painSum of 7 days' ratings0 = none

1 = mild

2 = moderate

3 = severe
×5
General well-beingSum of 7 days' ratings0 = generally well

1 = slightly under par

2 = poor

3 = very poor

4 = terrible
×7
Extraintestinal complicationsNumber of complications listedArthritis/arthralgia, iritis/uveitis, erythema nodosum, pyoderma gangrenosum, aphtous stomatitis, anal fissure/fistula/abscess, fever > 37.8 °C×20
Antidiarrhoeal drugsUse in the previous 7 days0 = no

1 = yes
×30
Abdominal mass0 = no

2 = questionable

5 = definite
×10
HaematocritExpected–observed haematocritMen: 47 observed

Women: 42 observed
×6
Body weightIdeal/observed ratio[1 − (ideal/observed)] × 100×1 (not < −10)
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

Cover of A Systematic Review and Economic Evaluation of the Use of Tumour Necrosis Factor-Alpha (TNF-α) Inhibitors, Adalimumab and Infliximab, for Crohn's Disease
A Systematic Review and Economic Evaluation of the Use of Tumour Necrosis Factor-Alpha (TNF-α) Inhibitors, Adalimumab and Infliximab, for Crohn's Disease.
Health Technology Assessment, No. 15.6.
Dretzke J, Edlin R, Round J, et al.
Southampton (UK): NIHR Journals Library; 2011 Feb.

Download

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...